Seattle Clinical Research Center Contributes to FDA Approval of New Migraine Treatment
Seattle, WA – May 9, 2025 – Seattle Clinical Research Center (SCRC) is proud to share that a new treatment for migraine—Atzumi™ (dihydroergotamine) nasal powder—has been approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults. SCRC was one of the clinical trial sites for the pivotal Phase … Read more
